New Product Development Xeris Pharmaceuticals is actively developing innovative products like a glucagon product and a dual-hormone pump for diabetes, indicating potential sales opportunities in the healthcare sector for these cutting-edge solutions.

Strategic Partnerships The company has established partnerships with firms like Beta Bionics, Regeneron, showcasing collaborative efforts that could lead to cross-selling opportunities and expanded market reach through joint product offerings.

Financial Stability With a recent funding injection of $200 million and revenue in the range of $50-100 million, Xeris Pharmaceuticals exhibits financial health that can be leveraged to negotiate favorable terms, making it an attractive partner for B2B sales deals.

Retirement of CEO The retirement of the CEO, Paul Edick, presents an opportunity for sales representatives to engage with new leadership and establish fresh connections that could open doors for potential collaborations or contracts under the new management.

Addressing Compliance Issues Despite past issues with promotional practices, such as with Recorlev, addressing compliance concerns can lead to rebuilding trust and fostering new business relationships, enabling sales reps to capitalize on a reformed image and emphasize the company's commitment to ethical practices.